Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

Volatile organic compounds up hypertension risk

A recent study has found epidemiological evidence pointing to an association between environmental pollutants and hypertension. This finding calls attention to the contribution of nonoccupational volatile organic compounds (VOCs) to the risk of hypertension in the general population.

Volatile organic compounds up hypertension risk

27 Dec 2024

Mitapivat cuts transfusion burden in TD thalassaemia

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.

Mitapivat cuts transfusion burden in TD thalassaemia

New UC guideline endorses early use of advanced therapies

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

Novel vaccine passes phase II trial in virally suppressed CHB

Therapeutic vaccination with ChAdOx1-HBV/MVA-HBV (VTP-300) has generated CD4+ and CD8+ cells and reduced HBsAg in a subset of chronic hepatitis B (CHB) patients with baseline values <100 IU/ml, as shown in a phase Ib/IIa trial. Moreover, a significant decrease in surface antigen occurs when the vaccine is combined with low-dose nivolumab.

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024 bởi

In the final 2-year analysis of the EBMT-SAAWP* RACE** study, the addition of eltrombopag to standard immunosuppressive treatment (IST) comprising horse antithymocyte globulin (hATG) plus cyclosporin A (CsA) improves long-term outcomes as frontline therapy for severe aplastic anaemia/very severe aplastic anaemia (SAA/vSAA).

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

Long-term nitrogen exposure linked to wider consequences

People exposed to nitrogen (NO2) in the long term are at risk of a range of diseases, including cardiovascular, respiratory, and musculoskeletal diseases, according to a study conducted in China.

Long-term nitrogen exposure linked to wider consequences